Back to Search Start Over

Prognostic accuracy of biomarkers of immune and endothelial activation in Mozambican children hospitalized with pneumonia.

Authors :
Balanza N
Erice C
Ngai M
McDonald CR
Weckman AM
Wright J
Richard-Greenblatt M
Varo R
López-Varela E
Sitoe A
Vitorino P
Bramugy J
Lanaspa M
Acácio S
Madrid L
Baro B
Kain KC
Bassat Q
Source :
PLOS global public health [PLOS Glob Public Health] 2023 Feb 23; Vol. 3 (2), pp. e0001553. Date of Electronic Publication: 2023 Feb 23 (Print Publication: 2023).
Publication Year :
2023

Abstract

Pneumonia is a leading cause of child mortality. However, currently we lack simple, objective, and accurate risk-stratification tools for pediatric pneumonia. Here we test the hypothesis that measuring biomarkers of immune and endothelial activation in children with pneumonia may facilitate the identification of those at risk of death. We recruited children <10 years old fulfilling WHO criteria for pneumonia and admitted to the Manhiça District Hospital (Mozambique) from 2010 to 2014. We measured plasma levels of IL-6, IL-8, Angpt-2, sTREM-1, sFlt-1, sTNFR1, PCT, and CRP at admission, and assessed their prognostic accuracy for in-hospital, 28-day, and 90-day mortality. Healthy community controls, within same age strata and location, were also assessed. All biomarkers were significantly elevated in 472 pneumonia cases versus 80 controls (p<0.001). IL-8, sFlt-1, and sTREM-1 were associated with in-hospital mortality (p<0.001) and showed the best discrimination with AUROCs of 0.877 (95% CI: 0.782 to 0.972), 0.832 (95% CI: 0.729 to 0.935) and 0.822 (95% CI: 0.735 to 0.908), respectively. Their performance was superior to CRP, PCT, oxygen saturation, and clinical severity scores. IL-8, sFlt-1, and sTREM-1 remained good predictors of 28-day and 90-day mortality. These findings suggest that measuring IL-8, sFlt-1, or sTREM-1 at hospital presentation can guide risk-stratification of children with pneumonia, which could enable prioritized care to improve survival and resource allocation.<br />Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: KCK is a named inventor on a patent “Biomarkers for early determination of a critical or life-threatening response to illness and/or treatment response” held by the University Health Network. EL-V is an editorial board member of PLOS Global Public Health. The remaining authors declare no competing interests.<br /> (Copyright: © 2023 Balanza et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Details

Language :
English
ISSN :
2767-3375
Volume :
3
Issue :
2
Database :
MEDLINE
Journal :
PLOS global public health
Publication Type :
Academic Journal
Accession number :
36963048
Full Text :
https://doi.org/10.1371/journal.pgph.0001553